Beyond One-Off Donations: How a 10-Year Sickle Cell Partnership Is Providing Ongoing Support
ONYINYECHI NWAIGBA 
For families managing sickle cell disorder, the cost of care does not arrive as a one-time bill. Medication, healthcare services and other forms of support can become recurring expenses, placing sustained pressure on household finances.
That is why a recent intervention by Dufil Prima Foods to provide free essential medication to 200 people living with Sickle Cell Disorder is significant for more than the immediate relief it offers.
The intervention, delivered through Dufil’s partnership with the Sickle Cell Foundation Nigeria (SCFN), is part of the “Hope Begins with Care” initiative and marks another phase in a partnership that has now lasted a decade.
The outreach, held at the Sickle Cell Foundation in Lagos, is aimed at reducing both the medical and financial burden associated with managing the lifelong condition.
For Dufil, the intervention represents a continued commitment to supporting vulnerable communities. For beneficiaries and their families, it means one less immediate healthcare expense to carry.
But perhaps the more important story is what happens when corporate social responsibility moves beyond a one-off donation and becomes a sustained partnership.
When Healthcare Costs Become a Household Burden
Managing sickle cell disorder can require continuous care, making the financial implications extend far beyond hospital visits.
Caleb Audu, Senior Manager at the Sickle Cell Foundation Nigeria, highlighted the scale of the challenge, noting that the cost of sickle cell management can push affected families into severe economic hardship.
For some families, healthcare expenses can compete directly with other basic needs.
Beneficiaries of the latest intervention said the reduction in medication costs would allow their families to redirect scarce resources towards necessities including food, education, rent and clothing.
That detail is important because it shows how healthcare interventions can have effects beyond health outcomes.
When a family no longer has to allocate as much of its income to essential medication, some of those resources can potentially be redirected to other areas of household wellbeing.
In this sense, healthcare support can also become an intervention in household financial resilience.
Why the 10-Year Partnership Matters
Corporate giving often attracts attention when a company announces a major donation or launches a new initiative.
But social challenges such as sickle cell disorder rarely respond to one-off interventions.
The condition is lifelong, which means the need for care, awareness and support continues long after an individual outreach programme ends.
Dufil’s partnership with SCFN has now entered its tenth year, with the organisations continuing to provide support through medication, healthcare and public awareness.
That continuity changes the nature of the intervention.
Rather than responding to a need once and moving on, a long-term partnership creates an opportunity to understand the needs of beneficiaries over time and develop interventions around those needs.
The partnership has also included previous community-focused interventions. In 2025, Dufil and SCFN organised the Makoko Community Sickle Cell Outreach Programme, which provided healthcare services, genotype awareness, health education and training for primary healthcare workers.
This suggests an approach that extends beyond the distribution of medication to include awareness, prevention and strengthening knowledge within communities.
From Medication to Awareness
The latest intervention also highlights an important part of sickle cell advocacy: awareness.
Temitope Ashiwaju, Group Corporate Communications and Events Manager at Dufil Prima Foods, stressed that advocacy and awareness should involve beneficiaries and stakeholders themselves.
He also highlighted genotype awareness and compatibility, particularly among young Nigerians making decisions about marriage and family life.
This adds another dimension to the partnership.
While medication provides immediate support to people already living with the disorder, awareness can help address knowledge gaps around genotype and sickle cell inheritance.
It also creates room for conversations that can help people make informed decisions about their health and family planning.
For CSR programmes, this distinction matters.
An intervention can provide immediate relief while also investing in education that may contribute to longer-term social outcomes.
What Sustainable CSR Looks Like
The Dufil-SCFN partnership raises a broader question about what makes a corporate social responsibility programme sustainable.
The answer is not necessarily the size of a single donation.
It can also be measured by consistency, relevance and the ability of a programme to respond to an ongoing need.
In this case, the focus has remained on a clearly defined health challenge, while the partnership has evolved to include medication, healthcare support, awareness and community outreach.
That continuity is particularly relevant for issues where beneficiaries require repeated or long-term support.
A company can donate medication once and generate immediate goodwill. But maintaining a partnership for ten years requires a different level of commitment.
It creates an opportunity for the company and its implementation partner to build institutional knowledge, understand beneficiary needs and improve the way interventions are delivered.
The Human Impact Behind the Numbers
The latest programme has 200 beneficiaries, but the impact extends beyond the number of people who received medication.
Every beneficiary represents a household that may be dealing with the financial and emotional demands of managing sickle cell disorder.
One of the beneficiaries, 16-year-old Farida Adedeji, who was diagnosed with the condition at the age of two, described the intervention as timely and impactful.
Her experience puts a human face to an issue that can easily become reduced to statistics.
For a family managing a lifelong condition, support with essential medication can mean being able to allocate limited income to another urgent household need.
That is where the social value of healthcare-focused CSR becomes more tangible.
Beyond the Corporate Contribution
While corporate interventions can provide valuable support, partnerships with organisations such as SCFN also demonstrate why collaboration matters in addressing complex social challenges.
The Sickle Cell Foundation Nigeria already operates programmes covering areas including free drug administration, leg ulcer management, stroke prevention, genetic testing, psychosocial support and healthcare-worker capacity development.
This existing infrastructure allows corporate support to connect with established expertise and services rather than operating in isolation.
For companies seeking to create meaningful social impact, this can be an important lesson: the most effective intervention may not always be building something new, but strengthening an organisation already working in the community.
Measuring What Ten Years of Support Has Achieved
The tenth year of the Dufil-SCFN partnership provides an opportunity to look beyond individual interventions and consider the cumulative impact of sustained support.
How many people have received medication over the decade?
How many communities have been reached through awareness campaigns?
How many healthcare workers have received training?
And, perhaps most importantly, has sustained support helped reduce some of the financial and social burden experienced by families living with sickle cell disorder?
These are the kinds of questions that can help move CSR reporting from simply documenting activities to examining outcomes.
A company can report how much it spent and how many people it reached. But the deeper measure of social impact is what changed for those people afterwards.
A Partnership That Goes Beyond the Donation
Dufil Prima Foods’ latest support for 200 people living with sickle cell disorder demonstrates the immediate value of providing access to essential medication.
But the bigger story is the decade-long partnership behind the intervention.
The collaboration between Dufil and the Sickle Cell Foundation Nigeria shows how sustained corporate support can combine immediate assistance with healthcare services, public awareness and community outreach.
As companies increasingly position CSR as part of their broader social-impact commitments, long-term partnerships such as this offer an important point of reference.
The most meaningful corporate interventions may not always be the ones with the biggest headlines or the largest one-time donations.
Sometimes, impact is built through showing up repeatedly for the same community, understanding a problem that does not disappear after one campaign and continuing to invest in solutions that meet an ongoing need.
For the 200 beneficiaries receiving support today, that commitment provides immediate relief.
For the wider sickle cell community, the greater value may lie in ensuring that healthcare support, awareness and advocacy remain part of the conversation long after the latest outreach ends.
[give_form id="20698"]
